Therapy related coagulopathies
Heparin - low molecular weight
Reviewer: Jeremy Parsons, M.D. (see Reviewers page)
Revised: 13 June 2012, last major update June 2012
Copyright: (c) 2002-2012, PathologyOutlines.com, Inc.
● Can be used instead of standard heparin for many patients, with similar efficacy and safety
● Produced by breaking heparin into shorter polysaccharide chains
● Molecular weight is approximately 5,000 daltons
● Less likely to bind to acute phase reactant proteins, platelets, platelet factor 4, macrophages and other sites, due to its shorter length
● Has more predictable anticoagulant effect than standard heparin, less need for laboratory monitoring, lower incident of heparin induced thrombocytopenia, greater bioavailability
● Longer half life than standard heparin (4 vs. 1.5 hours), which is prolonged in renal failure
● Inhibits factor Xa by 2 to 4x more than factor IIa, so does not substantially prolong PT and PTT
● Typically do not monitor except for periodic platelet counts
● Indications for monitoring include pregnancy, renal failure, obesity, prolonged use, infants and children, patients at high risk for bleeding / thrombosis
● Monitor by measuring anti-factor Xa activity, drawn 4 hours after injection
● Typical therapeutic range is 0.6 to 1.0 U/ml for twice a day dosing, higher for once a day dosing, 1.0 to 2.0 U/ml for prophylactic dosing
● Effects are reversed with protamine sulfate
Function of LMWH
● Clin Lab Med 2009;29:283
End of Coagulation > Therapy related coagulopathies > Heparin - low molecular weight
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.
All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).